ImageneBio (IMA) Non Operating Interest Expenses (2022 - 2023)
ImageneBio's (IMA) quarterly Non Operating Interest Expenses came in at $14000.0 in Q4 2023, up 566.67% year-over-year from $2100.0 in Q4 2022, and up 600.0% quarter-over-quarter from $2000.0 in Q3 2023.
Powered by 
Analysis
ImageneBio (IMA) Non Operating Interest Expenses (2022 - 2023) Analysis & Trends
ImageneBio has disclosed Non Operating Interest Expenses across 2 years of filings, most recently posting $14000.0 for Q4 2023.
- In Q4 2023, Non Operating Interest Expenses rose 566.67% year-over-year to $14000.0; the TTM figure through Dec 2023 stood at $19000.0 (down 81.9% YoY), while the FY2023 annual figure was $22000.0, up 120.0% from the prior year.
- Non Operating Interest Expenses came in at $14000.0 for Q4 2023 at ImageneBio, up from $2000.0 in the prior quarter.
- In the past five years, Non Operating Interest Expenses ranged from a high of $49000.0 in Q1 2022 to a low of -$3000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | ImageneBio | 42.89 Mn | -92.46 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 14,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 6,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Sep 30, 2022 | 12,000.00 |
| Jun 30, 2022 | 47,000.00 |
| Mar 31, 2022 | 49,000.00 |